The role of neurotrophic factors in regeneration of the nervous system;Rola czynników neurotroficznych w procesach regeneracji układu nerwowego

Neurologia i Neurochirurgia Polska

Volumn 46, Issue 6, 2012, Pages 579-590

  Machaliński, Bogusław ^a   Łazewski Banaszak, Piotr ^a   Dabkowska, Elzbieta ^a   Paczkowska, Edyta ^a   Gołab Janowska, Monika ^a   Nowacki, Przemysław ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Neurodegenerative diseases; Neurotrophic factors; Neurotrophic receptors; Stem cell based therapy

Indexed keywords

NEUROTROPHIC FACTOR; RECEPTOR;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CELL TRANSPLANTATION; GENE THERAPY; HOMEOSTASIS; HUMAN; NERVOUS SYSTEM; NERVOUS TISSUE; PARKINSON DISEASE; REGENERATION; STEM CELL; WNT SIGNALING PATHWAY;

EID: 84875195872     PISSN: 00283843     EISSN: 18974260     Source Type: Journal    
DOI: 10.5114/ninp.2012.32354     Document Type: Review

References (77)

1. Ramón y Cajal S. Degeneration and regeneration of the nervous system. Oxford University Press, New York 1928.
2. Cohen S., Levi-Montalcini R. Purification and properties of a nerve growth-promoting factor isolated from mouse sarcoma 180. Cancer Res 1957; 17: 15-20.
3. Lindholm P., Saarma M. Novel CDNF/MANF family of neurotrophic factors. Dev Neurobiol 2010; 70: 360-371.
4. Meloni M., Caporali A., Graiani G., i wsp. Nerve growth factor promotes cardiac repair following myocardial infarction. Circ Res 2010; 106: 1275-1284.
5. Vahlsing H.L., Hagg T., Spencer M., i wsp. Dose-dependent responses to nerve growth-factor by adult rat cholinergic medial septum and neostriatum neurons. Brain Res 1991; 552: 320-329.
6. Huang E.J., Reichardt L. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 2001; 24: 677-736.
7. Giulian D., Young D.G., Woodward J., i wsp. Interleukin-1 is an astroglial growth factor in the developing brain. J Neurosci 1988; 8: 709-714.
8. Barde Y.A., Edgar D., Thoenen H. Purification of a new neurotrophic factor from mammalian brain. EMBO J 1982; 1: 549-553.
9. Seebach B.S., Arvanov V., Mendell L.M., i wsp. Effects of BDNF and NT-3 on development of Ia/motoneuron functional connectivity in neonatal rats. J Neurophysiol 1999; 81: 2398-2405.
10. Enforns P., Van De Water T., Loring J., i wsp. Complementary roles of BDNF and NT-3 in vestibular and auditory development. Neuron 1995; 14: 1153-1164.
11. Kornblum H.I., Sankar R., Shin D.H., i wsp. Induction of brainderived neurotrophic factor mRNA by seizures in neonatal and juvenile rat brain. Mol Brain Res 1997; 44: 219-228.
12. Lom B., Cohen-Cory S. Brain-derrived neurotrophic factor differentially regulates retinal ganglion cells and axonal arborization in vivo. J Neurosci 1999; 19: 9928-9938.
13. Riddle D.R., Lo D.C., Katz L.C. NT-4 mediated rescue of lateral geniculate neurons from effects of monocular deprivation. Nature 1995; 378: 189-191.
14. Ibáńez C.F. Neurotrophin-4: the odd one out in the neurotrophin family. Neurochem Res 1996; 21: 787-793.
15. Yasuhara T., Shingo T., Date I. Glial cell line-derrived neurotrophic factor (GDNF) therapy for Parkinson's disease. Acta Med Okayama 2007; 61: 51-56.
16. Marciniak K., Butwicka A., Nowak J.Z. PEDF - endogenny czynnik o silnym działaniu neuroprotekcyjnym, neurotroficznym i antyangiogennym. Postepy Hig Med Dosw (Online) 2006; 60: 387-396.
17. Airavaara M., Chiocco M.J., Howard D.B., i wsp. Widespread cortical expression of MANF by AAV serotype 7: localization and protection against ischemic brain injury. Exp Neurol 2010; 225: 104-113.
18. Sun Z.P., Gong L., Huang S.H., i wsp. Intracellular trafficking and secretion of cerebral dopamine neurotrophic factor in neuro secretory cells. J Neurochem 2011; 117: 121-132.
19. Nowak J.Z., Zawilska J.B. Receptory i mechanizmy przekazywania sygnału. PWN, Warszawa 2004, s. 525-551.
20. Longstaff A. Krótkie wykłady. Neurobiologia. PWN, Warszawa 2002, ss. 461-468.
21. Kuan C.Y., Yang D.D., Roy D.R.S., i wsp. The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development. Neuron 1999; 22: 667-676.
22. Andressoo J.O., SaarmaM. Signalling mechanisms underlying development and maintenance of dopamine neurons. Curr Opin Neurobiol 2008; 18: 297-306.
23. Zawioelak D., Ostrowska M., Golenia A., i wsp. The -A162G polymorphism of the PON1 gene and the risk of sporadic amyotrophic lateral sclerosis. Neurol Neurochir Pol 2010; 44: 246-250.
24. Mitchell J.D., Borasio G.D. Amyotrophic lateral sclerosis. Lancet 2007; 369: 2031-2041.
25. Miller R.G., Mitchell J.D., Lyon M., i wsp. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2007; 1: CD001447.
26. BDNF Group. A controlled trial of recombinant methionyl human BDNF in ALS: the BDNF Study Group (Phase III). Neurology 1999; 53: 1427-1433.
27. Ochs G., Penn R.D., York M., i wsp. A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor ad ministered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 201-206.
28. Bognioanni P., Reali C., Sogos V. Cilliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Syst Rev 2004; 3: CD004302.
29. Grundstrom E., Lindholm D., Johansson A., i wsp. GDNF but not BDNF is increased in cerebrospinal fluid in amyotrophic lateral sclerosis. Neuroreport 2000; 11: 1781-1783.
30. Jiang Y.M., Yamamoto M., Kobayashi Y., i wsp. Gene expression profile of spinal motor neuorons in sporadic amyotrophic lateral sclerosis. Ann Neurol 2005; 57: 236-251.
31. Patel N.K., Bunnage M., Plaha P., i wsp. Intraputamental infusion of glial cell line-derived neurotrophic factor in PD: a twoyear outcome study. Ann Neurol 2005; 57: 298-302.
32. Bilak M.M., Corse A.M., Kuncl R.W. Additivity and potentation of IGF-1 and GDNF in the complete rescue of postnatal motor neurons. Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2: 83-91.
33. Lai E.C., Felice K.J., Festoff B.W., i wsp. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology 1997; 49: 1621-1630.
34. Borasio G.D., Robberecht W., Leigh P.N., i wsp. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 1998; 51: 583-586.
35. Sorenson E.J., Windbank A.J., Mandrekar J.N., i wsp. Subcutaneous IGF-I is not beneficial in 2-year ALS trial. Neurology 2008; 17: 1770-1775.
36. Lambrechts D., Storkebaum E., Morimoto M., i wsp. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protect motoneurons against ischemic death. Nat Genet 2003; 34: 383-394.
37. Devos D., Morean C., Lassalle P., i wsp. Low levels of the vascular endothelial growth factor in CSF from early ALS patients. Neurology 2004; 62: 2127-2129.
38. Kadoyama K., Funakoshi H., Ohya W., i wsp. Hepatocyte growth factor (HGF) attenuates gliosisand motoneurnal degeneration in the brainstem motor nuclei of transgenic mouse model of ALS. Neurosci Res 2007; 59: 446-456.
39. Madhavan R., Peng H.B. HGF induction of postsynaptic specializations at the neuromuscular junction. J Neurobiol 2006; 66: 134-147.
40. Gonzalez A.M., Buscaglia M., Ong M., i wsp. Distribution of basic fibroblast growth factor in the 18-day rat fetus: localization in the basement membrane of diverse tissues. J Cell Biol 1990; 110: 753-765.
41. Cassina P., Pehar M., Vargas M., i wsp. Astrocyte activation by fibroblast growth factor-1 and motor neuron apoptosis implications for amyotrophic lateral sclerosis. J Neurochem 2005; 93: 38-46.
42. Ehrenreich H., Timner W., Siren A.L. A novel role for an established player: anemia drug erythropoietin for the treatment of cerebral hypoxia/ischemia. Transfus Apher Sci 2004; 31: 39-44.
43. Toth C., Martinez J.A., Lin W.Q., i wsp. Local erythropoietin signaling enhances regeneration in peripheral axons. Neuroscience 2008; 154: 767-783.
44. Lauria G., Campanella A., Filippini G., i wsp. Erythropoietin in amyotrophic lateral sclerosis: A pilot, randomized, double-blind, placebo-controlled study of safety and tolerability. Neuromuscular Diseases Unit. Amyotroph Lateral Scler 2009; 10: 410-415.
45. Samyolenko A., Byts N., Rajalingam K., i wsp. Thrombopoietin inhibits nerbe growth factor-induced neuron al differentiation and ERK signalling. Cell 2008; 20: 154-162.
46. Schneider A., Kruger C., Steigleder T., i wsp. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest 2005; 115: 2083-2098.
47. Pitzer C., Klussmann S., Krüger C., i wsp. The hematopoietic factor granulocyte-colony stimulating factor improves outcome in experimental spinal cord injury. J Neurochem 2010; 113: 930-942.
48. Pitzer C., Krüger C, Plaas C., i wsp. Granulocyte-colony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosis. Brain 2008; 131: 3335-3347.
49. Cashman N., Tan L.Y., Krieger C., i wsp. Pilot study of granulocyte-colony stimulating factor (G-CSF)-mobilized peripheral blood stem cells in amyotrophic lateral sclerosis (ALS). Muscle Nerve 2008; 37: 620-625.
50. Nefussy B., Artamanov I., Deutsch V., i wsp. Recombinant human granulocyte-colony stimulating factor administration for treating amyotrophic lateral sclerosis: A pilot study. Amyotroph Lateral Scler 2010; 11: 187-193.
51. Gash D.M., Zhang Z., Ovadia A., i wsp. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996; 380: 252-255.
52. Zhang Z., Miyoshi Y., Lapchak P.A., i wsp. Dose response to intraventicular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys. J Pharmacol Exp Ther 1997; 282: 1396-1401.
53. Hoffer B.J., Hoffman A., Bowenkamp K., i wsp. Glial cell Linederived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci Lett 1994; 182: 107-111.
54. Kearns C.M., Gash D.M. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res 1995; 672: 104-111.
55. Kearns C.M., Cass W.A., Smoot K., i wsp. GDNF protection against 6-OHDA: time dependence and requirement for protein synthesis. J Neurosci 1997; 17: 7111-7118.
56. Lindvall O., Wahlberg L.U. Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease? Exp Neurol 2008; 209: 82-88.
57. Nutt J.G., Burchel K.J., Comella C.L., i wsp. Randomised, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2002; 60: 69-73.
58. Gill S.S., Patel N.K., Hotton G.R., i wsp. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson's disease. Nat Med 2003; 9: 589-594.
59. Lang A.E., Gill S.S., Patel N.K., i wsp. Randomized controlled trial of itraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson's disease. Ann Neurol 2006; 59: 459-466.
60. Slevin J.T., Gash D.M., Smith C.D., i wsp. Unilateral intraputamenal infusion of glial cell line-derived neurotrophic factor in patients with Parkinson's disease: response to 1 year of treatment and 1 year of withdrawal. J Neurosurg 2007; 106: 614-620.
61. Kaplitt M.G., Feigin A., Tang C., i wsp. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 2007; 369: 2097-2105.
62. Kierzynka A., KaŸmierski R., Kozubski W. Educational level and cognitive impairment in patients with Parkinson disease. Neurol Neurochir Pol 2011; 45: 24-31.
63. Lindholm P., Voutilainen M.H., Laurén J., i wsp. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature 2007; 448: 73-77.
64. Voutilainen M.H., Bäck S., Pörsti E., i wsp. Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease. J Neurosci 2009; 29: 9651-9659.
65. Paczkowska E., Dabkowska E., Nowacki P., i wsp. Terapia ko mórkowa w schorzeniach ośrodkowego układu nerwowego. Neurol Neurochir Pol 2009; 43: 550-558.
66. Li X.J., Du Z.W., Zarnowska E.D., i wsp. Specification of motoneurons from human embryonic stem cells. Nat Biotechnol 2005; 23: 215-221.
67. Dimos J.T., Rodolfa K.T., Niakan K.K., i wsp. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008; 321: 1218-1221.
68. Kucia M., Reca R., Campbell F.R., i wsp. A population of very small embryonic-like (VSEL) CXCR4(+)SSEA-1(+)Oct-4+stem cells identified in adult bone marrow. Leukemia 2006; 20: 857-869.
69. Paczkowska E., Kucia M., Koziarska D., i wsp. Clinical evidence that very small embryonic-like (VSEL) stem cells are mobilized into peripheral blood in patients after stroke. Stroke 2009; 40: 1237-1244.
70. Domanska-Janik K., Buzanska L., Lukomska B. A novel, neural potential of non-hematopoietic human umbilical cord blood stem cells. Int J Dev Biol 2008; 52: 237-248.
71. Li Y., Chen J., Zhang C.L., i wsp. Gliosis and brain remodeling after treatment of stroke in rats with marrow stromal cells. Glia 2005; 49: 407-417.
72. Suzuki M., McHugh J., Tork C., i wsp. GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS One 2007; 2: e689.
73. Mazzini L., Ferrero I., Luparello V., i wsp. Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: a phase I clinical trial. Exp Neurol 2010; 223: 229-237.
74. Sadan O., Bahat-Stromza M., Barhum Y., i wsp. Protective effects of neurotrophic factor-secreting cells in a 6-OHDA rat model of Parkinson disease. Stem Cells Dev 2009; 18: 1179-1190.
75. Crigler L., Robey R.C., Asawachaicharn A., i wsp. Human mesenchymal stem cell subpopulations express a variety of neuroregulatory molecules and promote neuronal cell survival and neuritogenesis. Exp Neurol 2006; 198: 54-64.
76. Wilkins A., Kemp K., Ginty M., i wsp. Human bone marrowderived mesenchymal stem cells secrete brain-derived neurotrophic factor which promotes neuronal survival in vitro. Stem Cell Res 2009; 3: 63-70.
77. Harper M.M., Grozdanic S.D., Blits B., i wsp. Transplantation of BDNF-secreting mesenchymal stem cells provides neuroprotection in chronically hypertensive rat eyes. Invest Ophthalmol Vis Sci 2011; 52: 4506-4515.